The Food and Drug Administration approved a new nasal spray Friday as the first needle-free emergency treatment for potentially fatal allergic reactions. The spray, which is made by ARS ...

Those at risk of a severe allergic reaction always have handy an EpiPen just in case. But soon their life might be saved by a spray in the nose rather than a needle to the thigh. Last week the FDA ...

is the only epinephrine nasal spray used for the emergency treatment of allergic reactions, including anaphylaxis in adults and children 4 years and older who weigh 33 lbs. or greater. is right for ...

neffy is the first epinephrine product approved for use out of a hospital setting in China for adults and children (>30 kg) living with severe allergic reactions Pediatrix Therapeutics, which has a ...

ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to ...

FDA approves Neffy 1 mg for children aged 4+ weighing 15 to <30 kg for allergic reactions. Most insured patients can access Neffy for $25, while cash price is $199 for two doses. Get our list of 10 ...

ARS as a commercial company. It was a year focused on building infrastructure, educating the market and learning as we ...

ARS Pharmaceuticals (NASDAQ:SPRY) reported first-quarter 2026 revenue of $22.7 million as executives said the company is ...

Add Yahoo as a preferred source to see more of our stories on Google. The Food and Drug Administration approved a new nasal spray Friday as the first needle-free emergency treatment for potentially ...

Add Yahoo as a preferred source to see more of our stories on Google. Aug. 26—Those at risk of a severe allergic reaction always have handy an EpiPen just in case. But soon their life might be saved ...